• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ImmunityBio, Inc. - Common Stock (NQ:IBRX)

    8.640 +0.390 (+4.73%)
    Streaming Delayed Price Updated: 12:07 PM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,316,440
    Open 8.240
    Bid (Size) 8.640 (1,100)
    Ask (Size) 8.650 (3,300)
    Prev. Close 8.250
    Today's Range 8.180 - 8.725
    52wk Range 1.950 - 12.43
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
    From ImmunityBio, Inc.
    Via Business Wire

    Performance

    YTD
    +327.7%
    +327.7%
    1 Month
    +23.6%
    +23.6%
    3 Month
    +9.5%
    +9.5%
    6 Month
    -9.4%
    -9.4%
    1 Year
    +263.0%
    +263.0%

    More News

    Read More
    News headline image
    Bull Finder: IBRX, ANY, GTE, JLHL Plus More Surging Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    ImmunityBio (NASDAQ:IBRX) Screens as a High-Growth Momentum Stock Passing Minervini’s Trend Template ↗
    Via Chartmill
    News headline image
    ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
    From Rosen Law Firm
    Via Business Wire
    News headline image
    IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    News headline image
    ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
    From SkyMedia, LLC
    Via GlobeNewswire
    News headline image
    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Why ImmunityBio Stock is Soaring Higher Today ↗
    Via The Motley Fool
    News headline image
    INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
    From Kessler Topaz Meltzer & Check, LLP
    Via Business Wire
    News headline image
    IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is ImmunityBio, Inc. - Common Stock publicly traded?
    Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
    What exchange does ImmunityBio, Inc. - Common Stock trade on?
    ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
    The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
    What is the current price of ImmunityBio, Inc. - Common Stock?
    The current price of ImmunityBio, Inc. - Common Stock is 8.640
    When was ImmunityBio, Inc. - Common Stock last traded?
    The last trade of ImmunityBio, Inc. - Common Stock was at 08/27/26 12:07 PM ET
    What is the market capitalization of ImmunityBio, Inc. - Common Stock?
    The market capitalization of ImmunityBio, Inc. - Common Stock is 3.38B
    How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
    ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.